Investor profile

D44 Ventures logo

D44 Ventures

Micro-fund

USHealthtechBio/PharmaDeep TechOther

See how your deck fits this investor's thesis, stage, and ticket size.

Analyse your fit

Investment thesis

D44 Ventures (operating as Dragonfly 44 Capital) is a neuroscience-focused fund building out a clinician network to close the development gap in brain health. The firm invests in neuroscience, brain health, BCI, and neurotech companies, leveraging a professional and clinician network to help portfolio companies grow. D44 delivers capital solutions and strategic advisory services to companies in neurotech, cognition, psychiatry, mental health, behavioral health, neurological conditions, and sleep, with a particular focus on private, preclinical companies with novel assets, strong IP, and differentiated development strategies — including next-generation neuropsychiatric drug development and ibogaine-related compounds.

Notable quotes

We believe that the real value in this field will not be captured only by the most visible public companies or the loudest narratives and instead still mostly sits in private, preclinical companies with novel assets, strong IP, and thoughtful development strategies.

Michael Brotherton · LinkedIn post by Michael Brotherton · 2025

In our view, this is one of the best moments to be evaluating the space. Policy is moving. Pharma is engaging. The capital markets are paying attention again. But the field is still early enough that many of the most compelling opportunities remain under-followed and asset-driven.

Michael Brotherton · LinkedIn post by Michael Brotherton · 2025

Meaningful progress in this field depends on multidisciplinary, in-person dialogue. When those conversations take place in nature, away from the usual pace and distractions, they create the kind of environment where deeper thinking, stronger connection, and better judgment can emerge.

Michael Brotherton · LinkedIn post by Dragonfly 44 Capital · 2026

Team

Michael Brotherton

Managing Partner

HealthtechBio/PharmaDeep Tech

Joe Hashmall

Team Member

HealthtechBio/Pharma

Recent investments

CompanyRoundSizeDate
Circular GenomicsUnknown
Autobahn TherapeuticsSeries C$100m2024
Seven StarlingUnknown

Frequent co-investors

VC firmDeals together
ARCH Venture Partners1
Newpath Partners1
Samsara BioCapital1
Canaan Partners1
Monograph Capital1
Insight Partners1

Fit check

Is D44 Ventures a match for your startup?

Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.

Analyse your fit